Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 23 of 23

List	Outcome	Time frame	Description
Secondary	Part 1 and Part 3: Clinical benefit rate (CBR, defined as CR, PR or SD)	First dose of study drug through at least 30 days after last dose of study drug.	CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease.
Secondary	Part 1 and Part 3: Progression-free survival (PFS)	First dose of study drug through at least 30 days after last dose of study drug.	PFS time is defined as the time from the participant's first dose of study drug (Day 1) to either the participant's disease progression or death, whichever occurs first.
Secondary	Part 1, Part 2 and Part 3: Duration of objective response (DOR)	First dose of study drug through at least 30 days after last dose of study drug.	DOR for a participant is defined as the time from the participant's initial objective response to study drug therapy to disease progression or death, whichever occurs first.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03000257/registered?page=2